Moreover, knockdown of NR4A1 or TXNDC5 by RNA interference also induced ROS in cancer cell lines suggesting that some ROS-inducing anticancer agents may also be NR4A1 ligands and that their anticancer activities may due, in part, to their activity as inverse NR4A1 agonists in cancer cells. This evidence concerns the gene TXNDC5 and cancer.